Varex Imaging reported non‑ GAAP EPS of $0.31 for Q3 FY26, topping the $0.21 consensus estimate. The beat, coupled with a 4% Revenue rise and $21 million Operating Cash Flow , signals improving margins and strengthens cash position ahead of its pending sale to Teledyne.

Key Highlights

  • EPS of $0.31 exceeded the $0.21 consensus, supporting a notable share price appreciation.
  • Third‑quarter revenue grew year‑over‑year, with medical sales leading the segment.
  • Operating cash flow generated $21 million.

Varex Imaging ( Nasdaq : VREX) posted non‑GAAP Earnings Per Share of $0.31 for the third quarter of fiscal 2026, comfortably above the $0.21 consensus estimate. Revenue rose year‑over‑year, while operating cash flow reached $21 million. The results were reflected in a noticeable uplift in the company’s share price, indicating strong market approval of the earnings outcome.

EPS Beats Forecast

The $0.31 non‑GAAP EPS contrasted with the $0.21 analyst expectation, delivering a clear beat that resonated with investors. The improvement was driven by higher Gross Profit , stemming from strong industrial sales and the accounting adjustments related to IEEPA Tariff reimbursements. GAAP Net Income per diluted share was $0.37, underscoring the earnings strength across both GAAP and non‑GAAP measures.

Financial Mechanics Unpacked

Product sales for the quarter, prior to the IEEPA adjustment, reflected solid Demand across industrial and cargo‑inspection lines. The company recouped tariffs from U.S. Customs and accounted for expected customer reimbursements, which together bolstered gross profit. Non‑GAAP gross Margin rose to 37%, while GAAP Operating Margin remained at 11%.

Cash and marketable securities totaled $99 million, supporting Liquidity for ongoing Research and Development initiatives.

Why the Market Reacts Now

Varex’s shares have risen appreciably, outperforming comparable peers in the imaging equipment sector. The earnings beat, combined with the generation of $21 million in cash flow and the narrowing spread between GAAP and non‑GAAP margins, signals the company’s capacity to sustain growth despite recent tariff considerations. Investors view the strengthened margins and solid cash position as a protective buffer against potential Supply ‑chain challenges, reinforcing Varex’s standing as a compelling player in the imaging market.

Industry Context

The broader industrial and medical imaging markets are experiencing a transition toward higher‑efficiency, lower‑cost solutions driven by advances in detector technology and increased regulatory scrutiny of radiation exposure. Companies that can enhance gross margins while maintaining operational cash flow are well‑positioned to capture expanding demand from sectors such as security screening, nondestructive testing, and healthcare diagnostics. Varex’s recent performance aligns with these industry trends, suggesting a favorable outlook for future periods.

Watch the Teledyne Transaction

The company has announced a pending transaction with Teledyne Technologies, leading to the cancellation of its earnings conference call and the postponement of guidance for the quarter. Completion of the deal will depend on Shareholder and regulatory approvals, offering a near‑term catalyst that could reshape Varex’s Capital Structure and broaden its market reach. The forthcoming fourth‑quarter earnings release will provide the next data point to assess whether the momentum observed in the third quarter can be sustained under new ownership.

Peers Moving on This News

  • Delcath Systems Inc (DCTH) down 0.7%
  • Neuropace Inc (NPCE) down 1.6%
  • Clearpoint Neuro Inc (CLPT) up 0.6%

Analysis based on the Form 8-K filed 10 August 2026.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making Investment decisions.